MetLife, Inc.

New York Stock Exchange
Back to all articles
Neutral 0

Here's Why Investors Should Stay Neutral on MetLife Stock for Now

AI-generated analysis

📈 MetLife stock has gained 4.5% over the past year, outperforming the industry's 2.3% decline.

💰 The company carries a Zacks Rank #3 (Hold) with a forward P/E of 7.97X versus an industry average of 8.77X.

📅 Analysts project 2026 earnings of $9.96 per share, representing a 12.8% year-over-year increase.

💵 Revenue is expected to reach $79.1 billion in 2026, implying a modest 0.3% growth.

📊 MetLife beat earnings estimates in three of the past four quarters with an average surprise of 2.4%.

🌍 Total premiums rose 3.4% year-over-year in Q1 2026, driven by strong sales in Japan, Korea, and Latin America.

📉 Variable investment income was volatile, reaching $518 million in Q1 2026 against a target of $1.6 billion for the full year.

⚠️ Return on invested capital (ROIC) stands at 1.8%, which is below the industry average of 2.2%.

💧 The company holds $22.7 billion in cash and equivalents, significantly exceeding its short-term debt of $404 million.

🔄 MetLife repurchased $950 million worth of shares in Q1 2026 and April 2026 combined.

📈 Its dividend yield of 2.9% is higher than the industry average of 2.6%.

🤖 The firm is leveraging artificial intelligence to improve customer experiences and streamline operational processes.

🏦 MetLife integrated PineBridge Investments to strengthen its asset management capabilities.

🌐 The company is entering a new phase of its "New Frontier" strategy focused on sustained earnings growth.

⚠️ Investors are advised to monitor sensitivity to private equity and real estate markets regarding investment income.

📉 Some analysts suggest better-ranked alternatives in the insurance space, such as Octave Specialty Group (Zacks Rank #1).

Bullish Signals
  • MetLife is well-poised for growth driven by higher premiums, cost-cutting efforts, strong cash generation, and strategic acquisitions.
  • The company trades at a forward P/E of 7.97X, which is lower than the industry average of 8.77X, indicating potential value.
  • MetLife holds a Value Score of A and has outperformed the industry with shares growing 4.5% over the past year versus an industry fall of 2.3%.
  • The consensus estimate for 2026 earnings is pegged at $9.96 per share, representing a 12.8% year-over-year rise that has been revised upward recently.
  • MetLife beat earnings estimates in three of the past four quarters with an average surprise of 2.4%, demonstrating consistent performance.
  • Total premiums rose 3.4% year over year in Q1 2026, supported by robust sales growth in Japan, Korea, and Latin America.
  • The company is entering the next phase of its New Frontier strategy to translate market leadership into sustained earnings growth.
  • MetLife has a strong liquidity position with $22.7 billion in cash and cash equivalents as of March 31, 2026, far exceeding short-term debt of $404 million.
  • The company returned capital to shareholders by buying back common shares worth $750 million in Q1 2026 and an additional $200 million in April 2026.
  • MetLife's dividend yield of 2.9% remains higher than the industry average of 2.6%, offering attractive income potential.
Risk Factors
  • MetLife's variable investment income has been volatile and remained below target at $1.5 billion in 2025 and $518 million in the first quarter of 2026.
  • The company's return on invested capital (ROIC) is 1.8%, which is below the industry average of 2.2%, indicating relatively weaker capital efficiency.
  • MetLife carries a Zacks Rank #3 (Hold), suggesting investors should remain neutral rather than bullish on the stock.
Full Analysis
MetLife (MET) is currently rated as a Zacks Rank #3 (Hold) with a forward P/E of 7.97X, which is below the industry average of 8.77X, and carries a Value Score of A. The company has a market capitalization of $53.3 billion and operates as an insurance-based global financial services firm offering protection and investment products to individual and institutional customers. Shares have grown 4.5% over the past year, outperforming the industry's 2.3% decline. The consensus estimate for MetLife's 2026 earnings is $9.96 per share, representing a 12.8% year-over-year increase, while revenues are pegged at $79.1 billion with a 0.3% rise. The company beat earnings estimates in three of the past four quarters with an average surprise of 2.4%. Growth is supported by its global franchise and diversified business mix, with total premiums rising 3.4% year over year in the first quarter of 2026 and revenues increasing 2.7% during the same period. MetLife is entering the next phase of its New Frontier strategy, focusing on translating market leadership into sustained earnings growth by leveraging favorable demographic trends like an aging population and rising retirement planning needs. The company is investing in technology modernization and artificial intelligence to improve customer experiences and streamline processes, while strengthening asset management capabilities through the integration of PineBridge Investments. Financially, MetLife holds $22.7 billion in cash and cash equivalents as of March 31, 2026, far exceeding its short-term debt of $404 million, supporting shareholder returns through share repurchases and dividends with a yield of 2.9%. However, investors should monitor volatile variable investment income, which was below target at $1.5 billion in 2025 and $518 million in the first quarter of 2026, remaining sensitive to private equity and real estate markets. Additionally, MetLife's return on invested capital (ROIC) is 1.8%, below the industry average of 2.2%, indicating relatively weaker capital efficiency. The article also highlights other insurance stocks with Zacks Rank #1 ratings, such as Octave Specialty Group, Pelagos Insurance Capital, and The Hanover Insurance Group, suggesting they may offer stronger growth potential compared to MetLife's current hold rating.